BR9810729A - Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante - Google Patents

Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante

Info

Publication number
BR9810729A
BR9810729A BR9810729-1A BR9810729A BR9810729A BR 9810729 A BR9810729 A BR 9810729A BR 9810729 A BR9810729 A BR 9810729A BR 9810729 A BR9810729 A BR 9810729A
Authority
BR
Brazil
Prior art keywords
self
pharmaceutical composition
emulsifying formulation
composition
pharmaceutically acceptable
Prior art date
Application number
BR9810729-1A
Other languages
English (en)
Other versions
BR9810729B1 (pt
Inventor
Walter Morozowich
Ping Gao
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9810729A publication Critical patent/BR9810729A/pt
Publication of BR9810729B1 publication Critical patent/BR9810729B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)

Abstract

<B>COMPOSIçãO FARMACêUTICA PARA COMPOSTOS LIPOFìLICOS áCIDOS DISPOSTA COMO UMA FORMULAçãO AUTO-EMULSIFICANTE A presente invenção provê uma nova composição farmacêutica com base no uso de uma quantidade específica de amina básica que compreende um composto piranona como um agente farmaceuticamente ativo, uma amina básica em uma quantidade de cerca de 0,1% a cerca de 10% em peso da composição total, um ou mais solventes farmaceuticamente aceitáveis e um ou mais tensoativos farmaceuticamente aceitáveis. Além disto, a composição pode compreender, ainda, um ou mais óleos farmaceuticamente aceitáveis. A composição está disposta como uma formulação auto-emulsificante que provê alta concentração e biodisponibilidade oral para compostos piranona lipofílicos.
BRPI9810729-1A 1997-07-29 1998-07-27 composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante. BR9810729B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5401297P 1997-07-29 1997-07-29
PCT/US1998/014817 WO1999006044A1 (en) 1997-07-29 1998-07-27 Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation

Publications (2)

Publication Number Publication Date
BR9810729A true BR9810729A (pt) 2000-08-08
BR9810729B1 BR9810729B1 (pt) 2010-07-13

Family

ID=21988155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810729-1A BR9810729B1 (pt) 1997-07-29 1998-07-27 composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.

Country Status (25)

Country Link
US (1) US6231887B1 (pt)
EP (1) EP0989851B1 (pt)
JP (1) JP4524367B2 (pt)
KR (1) KR100509131B1 (pt)
CN (1) CN1112927C (pt)
AT (1) ATE225174T1 (pt)
AU (1) AU728626B2 (pt)
BR (1) BR9810729B1 (pt)
CA (1) CA2294033C (pt)
CY (1) CY2006002I2 (pt)
CZ (1) CZ296957B6 (pt)
DE (1) DE69808463T2 (pt)
DK (1) DK0989851T3 (pt)
ES (1) ES2184310T3 (pt)
FI (1) FI20000172A (pt)
HK (1) HK1028879A1 (pt)
HU (1) HU228923B1 (pt)
NO (1) NO323425B1 (pt)
NZ (1) NZ502566A (pt)
PL (1) PL192865B1 (pt)
PT (1) PT989851E (pt)
RU (1) RU2202346C2 (pt)
SI (1) SI0989851T1 (pt)
SK (1) SK284616B6 (pt)
WO (1) WO1999006044A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
ES2234582T3 (es) * 1999-03-31 2005-07-01 PHARMACIA &amp; UPJOHN COMPANY LLC Emulsiones farmaceuticas para inhibidores de proteasas retrovirales.
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ATE381922T1 (de) 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
NZ543250A (en) * 2003-04-02 2008-12-24 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis C viral protease inhibitors
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CA2541398C (en) * 2003-10-07 2012-08-21 Eli Lilly And Company Liquid formulations of ractopamine
CA2583195A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP5028885B2 (ja) * 2006-07-04 2012-09-19 大正製薬株式会社 ユビデカレノン含有自己乳化組成物
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
ES2464367T3 (es) * 2009-07-07 2014-06-02 Boehringer Ingelheim International Gmbh Composición Farmacéutica para un Inhibidor de Proteasa del Virus de la Hepatitis C
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
RU2419426C1 (ru) * 2010-04-26 2011-05-27 Всеволод Иванович Киселев Лекарственное средство на основе дииндолилметана (dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
CN109745287A (zh) 2010-05-03 2019-05-14 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
DE3300793A1 (de) * 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5376688A (en) 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1996003113A1 (en) * 1994-07-22 1996-02-08 G.D. Searle & Co. Self-emulsifying drug delivery system
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
NZ311646A (en) 1995-06-06 2000-02-28 Hoffmann La Roche Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
RU2202346C2 (ru) 2003-04-20
CY2006002I2 (el) 2012-01-25
KR20010022369A (ko) 2001-03-15
PL192865B1 (pl) 2006-12-29
PT989851E (pt) 2002-12-31
HU228923B1 (en) 2013-06-28
SI0989851T1 (en) 2003-04-30
NO323425B1 (no) 2007-04-30
AU8573898A (en) 1999-02-22
FI20000172A (fi) 2000-01-28
EP0989851B1 (en) 2002-10-02
DE69808463D1 (de) 2002-11-07
CN1261796A (zh) 2000-08-02
ES2184310T3 (es) 2003-04-01
HK1028879A1 (en) 2001-03-09
ATE225174T1 (de) 2002-10-15
PL338335A1 (en) 2000-10-23
NO20000466D0 (no) 2000-01-28
DE69808463T2 (de) 2003-06-26
JP2002510330A (ja) 2002-04-02
SK284616B6 (sk) 2005-07-01
NZ502566A (en) 2002-03-28
CZ2000156A3 (cs) 2000-05-17
WO1999006044A1 (en) 1999-02-11
US6231887B1 (en) 2001-05-15
CA2294033A1 (en) 1999-02-11
SK162000A3 (en) 2000-12-11
AU728626B2 (en) 2001-01-11
HUP0002440A3 (en) 2001-10-29
KR100509131B1 (ko) 2005-08-18
EP0989851A1 (en) 2000-04-05
CA2294033C (en) 2007-01-09
HUP0002440A2 (hu) 2001-09-28
CY2006002I1 (el) 2011-02-02
CZ296957B6 (cs) 2006-08-16
NO20000466L (no) 2000-03-28
CN1112927C (zh) 2003-07-02
BR9810729B1 (pt) 2010-07-13
DK0989851T3 (da) 2003-01-27
JP4524367B2 (ja) 2010-08-18

Similar Documents

Publication Publication Date Title
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
BR9811058A (pt) Formulação auto-emulsificante para compostos lipofìlicos
BR9810866A (pt) Composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR9813947A (pt) Composições tópicas para distribuição de droga nsai
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
BRPI0116237B8 (pt) &#34;composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina&#34;.
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
HRP20010243B1 (en) Compositions containing diphosphonic acids
BR0211729A (pt) Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
IT1272149B (it) Composizione farmeceutiche ad attivita&#39; analgesica
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
BR9810711A (pt) Formulação tópica de pulverização antipruriginosa, e, processo para prevenção ou tratamento de prurido em um paciente
IT1291278B1 (it) Preparazione farmaceutica a base di nimesulide per uso topico
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
BR0016241A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
BR9803129A (pt) Composto de (17alfa) - 17 hidróxi-11 metileno-19 norpregna-4,15-dieno-20-in-3-ona cristalino, composição farmacêutica sólida e processo para a preparação e uso do composto de (17alfa)-17-hidróxi-11-metileno-19 norpregna-4, 15-dieno-20-in-3-ona cristalino.
KR970705394A (ko) 연고제 (an ointment preparation)
SE8302976L (sv) Farmaceutiska kompositioner innehallande minst en polyflourerad alkohol
MX9207426A (es) Inhibidores de la reductasa de la 5-alfa-testosterona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

Free format text: NOME ALTERADO DE: PHARMACIA AND UPJOHN COMPANY

B25G Requested change of headquarter approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120005559/RJ DE 23/01/2012.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.07.2020